Immunotherapy (Checkpoint Inhibitors)

Eligibility depends on your cancer type, stage, biomarker status (PD-L1, MSI, TMB), and overall health. Your oncologist will review your tumor's molecular profile and medical history. Many cancers now have checkpoint inhibitors as first-line treatment. Key requirements include adequate organ function and ECOG performance status 0-2.

Response rates vary by cancer type. For cancers with high PD-L1 expression or MSI-H status, response rates can reach 40-60%. For unselected populations, rates are typically 15-25%. When responses occur, they can be durable, with some patients remaining disease-free for years. Your oncologist can provide more specific estimates based on your tumor profile.

Common warning signs include: new or worsening diarrhea (>4 stools/day), shortness of breath or new cough, skin rash covering large areas, unusual fatigue, headaches with vision changes, muscle weakness, or yellowing of eyes/skin. Report any new or unusual symptoms promptly to your oncology team. Early detection and treatment of irAEs leads to better outcomes.

Patients with well-controlled autoimmune conditions may be candidates with careful monitoring. About 27-33% may experience disease flares, but most are manageable with steroids. Conditions like rheumatoid arthritis or psoriasis are often manageable, while severe conditions like myasthenia gravis or those requiring high-dose immunosuppression require extra caution.

Treatment typically continues until disease progression or unacceptable toxicity. Some adjuvant (post-surgery) treatments are for a fixed duration, usually 1 year. Some patients in complete response may stop treatment after 2 years; data suggest many remain disease-free. Your oncologist will recommend the optimal duration based on your response and tolerance.

Many patients who stop due to manageable irAEs continue to benefit from treatment. Durable responses can persist even after treatment stops. Your oncologist may consider rechallenging with the same or a different checkpoint inhibitor if the irAE resolves and no other options exist. Some endocrine irAEs (like thyroid dysfunction) can be managed with hormone replacement while continuing therapy.

Drug development costs, complex manufacturing of antibody drugs, and lack of generic competition contribute to high prices. In the US, pembrolizumab alone represents over $4.8 billion in annual Medicare spending. Treatment in Thailand typically costs 25-35% less while using the same FDA-approved drugs, with annual savings of $50,000-80,000 for monotherapy.

Yes, this 'split care' model is common and well-supported. You can receive infusions in Thailand and have local oncologists manage routine monitoring and minor irAEs. Extended dosing schedules (every 6 weeks for pembrolizumab, every 4 weeks for nivolumab) reduce travel frequency. Ensure clear communication between your Thai and local oncology teams with comprehensive treatment summaries.

Subcutaneous formulations (pembrolizumab KEYTRUDA QLEX, nivolumab OPDIVO QVANTIG, atezolizumab TECENTRIQ HYBREZA) offer the same drug but are administered as injections under the skin in 3-5 minutes rather than 30-60 minute IV infusions. Efficacy and safety are equivalent. SC formulations improve convenience and reduce time at the cancer center.

Pseudoprogression occurs in 5-10% of patients when the tumor appears to grow on initial imaging due to immune cell infiltration, followed by shrinkage. If you feel clinically stable, your oncologist may continue treatment and repeat imaging in 4-8 weeks using iRECIST criteria to confirm whether it's true progression or pseudoprogression.

There are no strict dietary restrictions with checkpoint inhibitors. However, avoid supplements that boost immune function (echinacea, elderberry) as they may theoretically increase irAE risk. Inform your oncologist of all supplements. Maintain good nutrition and hydration. Live vaccines should be avoided during treatment.

Long-term survival has improved dramatically. In melanoma, 5-year survival for metastatic disease has increased from 5% to over 50% for some patients on combination therapy. In NSCLC with high PD-L1, 5-year survival rates now exceed 25-30%. Checkpoint inhibitors have fundamentally changed the prognosis for many cancer types, with some patients achieving durable complete responses.

Inactivated vaccines (flu, COVID-19, pneumococcal) are generally safe and recommended. Avoid live vaccines (MMR, yellow fever, live shingles vaccine) during treatment due to potential for uncontrolled infection. Timing vaccines appropriately with your treatment schedule is advised; discuss optimal timing with your oncologist.

Bring: pathology reports (ideally with tissue blocks or slides if possible for repeat biomarker testing), all imaging on CD/USB, complete treatment history summary, list of current medications, recent lab results, and any biomarker test results (PD-L1, MSI, NGS panels). Having records in English or professionally translated facilitates care coordination.